BioSpace News Archive

Global Cord Blood Corporation (NYSE: CO) (the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial re

While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.

Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received approval from Australia’s Therapeutic Goods Administration for the supply of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.

New parallel cohort will broaden evaluation of MCY-M11 in patients through inclusion of a preconditioning regimen and multiple dosing cycles

Vanda Pharmaceuticals Inc. reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 pneumonia in the ODYSSEY study.

Industry Veteran in Targeted Oncology Joins as Ikena Advances Multiple Clinical and Preclinical Programs

Fresenius Kabi announced it is introducing smart labels for a range of essential medications used in hospitals.

On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing

• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients across the U.S. SAN FRANCISCO and TAIPEI, Taiwan, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that it has dosed the first patient in its Phase 1 open-label, dose escalatio